Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SolastoTSE:6197 +0.54%48 EV-to-EBITDA is 11.03 as of Sep. 08, 2026, which is 7% below its 10-year median of 11.92. GuruFocus rates TSE:6197 with a GF Score™ of 48/100 and a GF Value™ of 円567.70 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Solasto ranks worse than 51.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Solasto's enterprise value is 円107,140 Mil.
Solasto's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円9,713 Mil. Therefore, Solasto's EV-to-EBITDA for today is 11.03.
The historical rank and industry rank for Solasto's EV-to-EBITDA or its related term are showing as below:
TSE:6197'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.42 Med: 11.92 Max: 25.19
Current: 11.03
During the past 11 years, the highest EV-to-EBITDA of Solasto was 25.19. The lowest was 4.42. And the median was 11.92.
TSE:6197's EV-to-EBITDA is ranked worse than 51.56% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.61
vs TSE:6197: 11.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-08), Solasto's stock price is 円1118.00.
Solasto's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円40.820. Therefore, Solasto's PE Ratio (TTM) for today is 27.39.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Solasto's share price for today is 円1118.00.
Solasto's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円40.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Solasto's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6197 vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Solasto's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasto EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Solasto's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Solasto's EV-to-EBITDA falls into.
Solasto's current Enterprise Value is 円107,140 Mil.
Solasto's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9,713 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasto (TSE:6197) has a EV-to-EBITDA of 11.03 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Solasto. This is near median its historical median of 11.92. Over the past decade, Solasto's EV-to-EBITDA has ranged from 4.42 to 25.19. According to the industry distribution chart, Solasto ranks #264 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 51.6%.
Is Solasto's EV-to-EBITDA too high?
Solasto's current EV-to-EBITDA of 11.03 is near median its 10-year median of 11.92. Over the past 10 years, this metric has ranged from a low of 4.42 to a high of 25.19. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.61. Solasto's value of 11.03 is 4% above this industry median. Based on the distribution chart, Solasto ranks #264 out of 512 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Solasto has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasto's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Solasto ranks #264 out of 512 companies for EV-to-EBITDA. This places Solasto in the lower half of its industry. The industry median EV-to-EBITDA is 10.61. Solasto's value of 11.03 is 4% above this benchmark. Historically, Solasto's own EV-to-EBITDA has ranged from 4.42 to 25.19 over the past decade. While the company's 10-year median is 11.92 vs. the industry median of 10.61, Solasto has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.61, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasto's current EV-to-EBITDA of 11.03 is 4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Solasto. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasto's current EV-to-EBITDA is 11.03, which is near median its own 10-year median of 11.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasto stock overvalued right now?
Based on GuruFocus' analysis, Solasto (TSE:6197) is currently considered Significantly Overvalued. The stock's GF Value™ is 円567.70, compared to a current price of 円1,118.00 — trading 96.9% above its estimated fair value. The current EV-to-EBITDA is 11.03, which is near median its 10-year median of 11.92 and 4% above the Healthcare Providers & Services industry median of 10.61. Solasto's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Solasto (TSE:6197), the current EV-to-EBITDA is 11.03 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasto (TSE:6197) Overvalued in 2026?
Based on GuruFocus' analysis, Solasto stock appears to be overvalued.
The current stock price of 円1,118.00 is trading 96.9% above its estimated GF Value™ of 円567.70.
GuruFocus considers Solasto to be Significantly Overvalued.
Key valuation signals for TSE:6197:
EV-to-EBITDA: 11.03 (near median its 10-year median of 11.92)
GF Value™: 円567.70 vs. price of 円1,118.00 (96.9% above fair value)
Industry Position: 4% above the Healthcare Providers & Services median (#264 of 512)
No single metric tells the full story. See the TSE:6197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6197 has been successfully added to your 
